Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus
Glucagon-like peptide-1 (GLP-1) receptor agonists are recently discovered antidiabetic drugs with potent hypoglycemic effects. Among different mechanisms of activity, these compounds were shown to reduce blood glucose by suppression of glucagon secretion and stimulation of glucose-dependent insulin...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2021, Vol.2021, p.1-7 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2021 |
| creator | Yaribeygi, Habib Atkin, Stephen L. Montecucco, Fabrizio Jamialahmadi, Tannaz Sahebkar, Amirhossein |
| description | Glucagon-like peptide-1 (GLP-1) receptor agonists are recently discovered antidiabetic drugs with potent hypoglycemic effects. Among different mechanisms of activity, these compounds were shown to reduce blood glucose by suppression of glucagon secretion and stimulation of glucose-dependent insulin secretion. These antidiabetic agents have a minor risk of hypoglycemia and have been suggested as a second-line therapy to be added to metformin treatment to further optimize glycemic control in diabetes. More recently, scientific evidence suggests that GLP-1 receptor agonists may particularly afford protection from diabetic nephropathy through modulation of the molecular pathways involved in renal impairment and so improve renal function. This additional benefit adds further weight for these compounds to become promising drugs not only for glycemic control but also to prevent diabetic complications. In this review, we have updated evidence on the beneficial effects of GLP-1 receptor agonists on diabetic nephropathy and detailed the underlying pathophysiological mechanisms. |
| doi_str_mv | 10.1155/2021/8163153 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8405289</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A683571372</galeid><sourcerecordid>A683571372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-e5e3ee970a03233261db7230dd1e543c069b13362ae1b9cb7abd6c74c2d638c53</originalsourceid><addsrcrecordid>eNp9kVtr3DAQhUVJacI2b_0Bhr4EUica3Wy_FHLZXCClUNJnIcvjrIJX2kp2Sv59ZHYJTR8iBjQwH2d0dAj5AvQEQMpTRhmc1qA4SP6BHDAOolQgYO-153yfHKb0SPPJIG3UJ7LPhahACXZAlr_Qh00MI9rRPWGx7PvcpSL0xa23EUfny3OTsCvuVxjN5rlwvrh0psURU_EDh8GNU_pMPvZmSHi4uxfk99Xy_uKmvPt5fXtxdldaUcNYokSO2FTUUM44Zwq6tmKcdh2gFNxS1bT5wYoZhLaxbWXaTtlKWNYpXlvJF-T7VncztWvsLPoxmkFvolub-KyDcfrtxLuVfghPuhZUsrrJAkc7gRj-TJhGvXbJZhfGY5iSZlLVspGVEBn9-h_6GKbos72Zathc_1APZkDtfB_yXjuL6jPVqLoCCfA-VXNZAc__sCDftpSNIaWI_asxoHqOW89x613cGT_e4ivnO_PXvU-_AGiNpMM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2569269264</pqid></control><display><type>article</type><title>Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus</title><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Yaribeygi, Habib ; Atkin, Stephen L. ; Montecucco, Fabrizio ; Jamialahmadi, Tannaz ; Sahebkar, Amirhossein</creator><contributor>Sakata, Naoaki ; Naoaki Sakata</contributor><creatorcontrib>Yaribeygi, Habib ; Atkin, Stephen L. ; Montecucco, Fabrizio ; Jamialahmadi, Tannaz ; Sahebkar, Amirhossein ; Sakata, Naoaki ; Naoaki Sakata</creatorcontrib><description>Glucagon-like peptide-1 (GLP-1) receptor agonists are recently discovered antidiabetic drugs with potent hypoglycemic effects. Among different mechanisms of activity, these compounds were shown to reduce blood glucose by suppression of glucagon secretion and stimulation of glucose-dependent insulin secretion. These antidiabetic agents have a minor risk of hypoglycemia and have been suggested as a second-line therapy to be added to metformin treatment to further optimize glycemic control in diabetes. More recently, scientific evidence suggests that GLP-1 receptor agonists may particularly afford protection from diabetic nephropathy through modulation of the molecular pathways involved in renal impairment and so improve renal function. This additional benefit adds further weight for these compounds to become promising drugs not only for glycemic control but also to prevent diabetic complications. In this review, we have updated evidence on the beneficial effects of GLP-1 receptor agonists on diabetic nephropathy and detailed the underlying pathophysiological mechanisms.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2021/8163153</identifier><identifier>PMID: 34471642</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Adenosine ; Agonists ; Amino acids ; Analysis ; Antidiabetics ; Antioxidants ; Apoptosis ; Blood glucose ; Blood sugar ; Care and treatment ; Complications ; Diabetes ; Diabetes mellitus ; Diabetic nephropathies ; Diabetic nephropathy ; Diabetic neuropathy ; Diabetic retinopathy ; Endocrine system ; Enzymes ; Free radicals ; GLP-1 receptor agonists ; Glucagon ; Glucagon-like peptide 1 ; Glucose ; Hypoglycemia ; Identification and classification ; Insulin ; Insulin secretion ; Kidneys ; Kinases ; Metabolism ; Metformin ; Nephropathy ; Oxidative stress ; Pathophysiology ; Peptide hormones ; Peptides ; Physiological aspects ; Properties ; Proteins ; Receptors ; Renal function ; Review ; Secretion ; Tumor necrosis factor-TNF</subject><ispartof>BioMed research international, 2021, Vol.2021, p.1-7</ispartof><rights>Copyright © 2021 Habib Yaribeygi et al.</rights><rights>COPYRIGHT 2021 John Wiley & Sons, Inc.</rights><rights>Copyright © 2021 Habib Yaribeygi et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2021 Habib Yaribeygi et al. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-e5e3ee970a03233261db7230dd1e543c069b13362ae1b9cb7abd6c74c2d638c53</citedby><cites>FETCH-LOGICAL-c481t-e5e3ee970a03233261db7230dd1e543c069b13362ae1b9cb7abd6c74c2d638c53</cites><orcidid>0000-0003-0823-8729 ; 0000-0002-8656-1444 ; 0000-0002-5887-7257</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405289/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405289/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4024,27923,27924,27925,53791,53793</link.rule.ids></links><search><contributor>Sakata, Naoaki</contributor><contributor>Naoaki Sakata</contributor><creatorcontrib>Yaribeygi, Habib</creatorcontrib><creatorcontrib>Atkin, Stephen L.</creatorcontrib><creatorcontrib>Montecucco, Fabrizio</creatorcontrib><creatorcontrib>Jamialahmadi, Tannaz</creatorcontrib><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><title>Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus</title><title>BioMed research international</title><description>Glucagon-like peptide-1 (GLP-1) receptor agonists are recently discovered antidiabetic drugs with potent hypoglycemic effects. Among different mechanisms of activity, these compounds were shown to reduce blood glucose by suppression of glucagon secretion and stimulation of glucose-dependent insulin secretion. These antidiabetic agents have a minor risk of hypoglycemia and have been suggested as a second-line therapy to be added to metformin treatment to further optimize glycemic control in diabetes. More recently, scientific evidence suggests that GLP-1 receptor agonists may particularly afford protection from diabetic nephropathy through modulation of the molecular pathways involved in renal impairment and so improve renal function. This additional benefit adds further weight for these compounds to become promising drugs not only for glycemic control but also to prevent diabetic complications. In this review, we have updated evidence on the beneficial effects of GLP-1 receptor agonists on diabetic nephropathy and detailed the underlying pathophysiological mechanisms.</description><subject>Adenosine</subject><subject>Agonists</subject><subject>Amino acids</subject><subject>Analysis</subject><subject>Antidiabetics</subject><subject>Antioxidants</subject><subject>Apoptosis</subject><subject>Blood glucose</subject><subject>Blood sugar</subject><subject>Care and treatment</subject><subject>Complications</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetic nephropathies</subject><subject>Diabetic nephropathy</subject><subject>Diabetic neuropathy</subject><subject>Diabetic retinopathy</subject><subject>Endocrine system</subject><subject>Enzymes</subject><subject>Free radicals</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucose</subject><subject>Hypoglycemia</subject><subject>Identification and classification</subject><subject>Insulin</subject><subject>Insulin secretion</subject><subject>Kidneys</subject><subject>Kinases</subject><subject>Metabolism</subject><subject>Metformin</subject><subject>Nephropathy</subject><subject>Oxidative stress</subject><subject>Pathophysiology</subject><subject>Peptide hormones</subject><subject>Peptides</subject><subject>Physiological aspects</subject><subject>Properties</subject><subject>Proteins</subject><subject>Receptors</subject><subject>Renal function</subject><subject>Review</subject><subject>Secretion</subject><subject>Tumor necrosis factor-TNF</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kVtr3DAQhUVJacI2b_0Bhr4EUica3Wy_FHLZXCClUNJnIcvjrIJX2kp2Sv59ZHYJTR8iBjQwH2d0dAj5AvQEQMpTRhmc1qA4SP6BHDAOolQgYO-153yfHKb0SPPJIG3UJ7LPhahACXZAlr_Qh00MI9rRPWGx7PvcpSL0xa23EUfny3OTsCvuVxjN5rlwvrh0psURU_EDh8GNU_pMPvZmSHi4uxfk99Xy_uKmvPt5fXtxdldaUcNYokSO2FTUUM44Zwq6tmKcdh2gFNxS1bT5wYoZhLaxbWXaTtlKWNYpXlvJF-T7VncztWvsLPoxmkFvolub-KyDcfrtxLuVfghPuhZUsrrJAkc7gRj-TJhGvXbJZhfGY5iSZlLVspGVEBn9-h_6GKbos72Zathc_1APZkDtfB_yXjuL6jPVqLoCCfA-VXNZAc__sCDftpSNIaWI_asxoHqOW89x613cGT_e4ivnO_PXvU-_AGiNpMM</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Yaribeygi, Habib</creator><creator>Atkin, Stephen L.</creator><creator>Montecucco, Fabrizio</creator><creator>Jamialahmadi, Tannaz</creator><creator>Sahebkar, Amirhossein</creator><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0823-8729</orcidid><orcidid>https://orcid.org/0000-0002-8656-1444</orcidid><orcidid>https://orcid.org/0000-0002-5887-7257</orcidid></search><sort><creationdate>2021</creationdate><title>Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus</title><author>Yaribeygi, Habib ; Atkin, Stephen L. ; Montecucco, Fabrizio ; Jamialahmadi, Tannaz ; Sahebkar, Amirhossein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-e5e3ee970a03233261db7230dd1e543c069b13362ae1b9cb7abd6c74c2d638c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenosine</topic><topic>Agonists</topic><topic>Amino acids</topic><topic>Analysis</topic><topic>Antidiabetics</topic><topic>Antioxidants</topic><topic>Apoptosis</topic><topic>Blood glucose</topic><topic>Blood sugar</topic><topic>Care and treatment</topic><topic>Complications</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetic nephropathies</topic><topic>Diabetic nephropathy</topic><topic>Diabetic neuropathy</topic><topic>Diabetic retinopathy</topic><topic>Endocrine system</topic><topic>Enzymes</topic><topic>Free radicals</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucose</topic><topic>Hypoglycemia</topic><topic>Identification and classification</topic><topic>Insulin</topic><topic>Insulin secretion</topic><topic>Kidneys</topic><topic>Kinases</topic><topic>Metabolism</topic><topic>Metformin</topic><topic>Nephropathy</topic><topic>Oxidative stress</topic><topic>Pathophysiology</topic><topic>Peptide hormones</topic><topic>Peptides</topic><topic>Physiological aspects</topic><topic>Properties</topic><topic>Proteins</topic><topic>Receptors</topic><topic>Renal function</topic><topic>Review</topic><topic>Secretion</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yaribeygi, Habib</creatorcontrib><creatorcontrib>Atkin, Stephen L.</creatorcontrib><creatorcontrib>Montecucco, Fabrizio</creatorcontrib><creatorcontrib>Jamialahmadi, Tannaz</creatorcontrib><creatorcontrib>Sahebkar, Amirhossein</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yaribeygi, Habib</au><au>Atkin, Stephen L.</au><au>Montecucco, Fabrizio</au><au>Jamialahmadi, Tannaz</au><au>Sahebkar, Amirhossein</au><au>Sakata, Naoaki</au><au>Naoaki Sakata</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus</atitle><jtitle>BioMed research international</jtitle><date>2021</date><risdate>2021</risdate><volume>2021</volume><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Glucagon-like peptide-1 (GLP-1) receptor agonists are recently discovered antidiabetic drugs with potent hypoglycemic effects. Among different mechanisms of activity, these compounds were shown to reduce blood glucose by suppression of glucagon secretion and stimulation of glucose-dependent insulin secretion. These antidiabetic agents have a minor risk of hypoglycemia and have been suggested as a second-line therapy to be added to metformin treatment to further optimize glycemic control in diabetes. More recently, scientific evidence suggests that GLP-1 receptor agonists may particularly afford protection from diabetic nephropathy through modulation of the molecular pathways involved in renal impairment and so improve renal function. This additional benefit adds further weight for these compounds to become promising drugs not only for glycemic control but also to prevent diabetic complications. In this review, we have updated evidence on the beneficial effects of GLP-1 receptor agonists on diabetic nephropathy and detailed the underlying pathophysiological mechanisms.</abstract><cop>New York</cop><pub>Hindawi</pub><pmid>34471642</pmid><doi>10.1155/2021/8163153</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0823-8729</orcidid><orcidid>https://orcid.org/0000-0002-8656-1444</orcidid><orcidid>https://orcid.org/0000-0002-5887-7257</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2021, Vol.2021, p.1-7 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8405289 |
| source | PubMed Central Open Access; Wiley-Blackwell Open Access Titles; PubMed Central; Alma/SFX Local Collection |
| subjects | Adenosine Agonists Amino acids Analysis Antidiabetics Antioxidants Apoptosis Blood glucose Blood sugar Care and treatment Complications Diabetes Diabetes mellitus Diabetic nephropathies Diabetic nephropathy Diabetic neuropathy Diabetic retinopathy Endocrine system Enzymes Free radicals GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucose Hypoglycemia Identification and classification Insulin Insulin secretion Kidneys Kinases Metabolism Metformin Nephropathy Oxidative stress Pathophysiology Peptide hormones Peptides Physiological aspects Properties Proteins Receptors Renal function Review Secretion Tumor necrosis factor-TNF |
| title | Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T12%3A59%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Renoprotective%20Effects%20of%20Incretin-Based%20Therapy%20in%20Diabetes%20Mellitus&rft.jtitle=BioMed%20research%20international&rft.au=Yaribeygi,%20Habib&rft.date=2021&rft.volume=2021&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2021/8163153&rft_dat=%3Cgale_pubme%3EA683571372%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2569269264&rft_id=info:pmid/34471642&rft_galeid=A683571372&rfr_iscdi=true |